Zhan Lingjun, Deng Wei, Bao Linlin, Lv Qi, Ma Chunmei, Li Fengdi, Xu Lili, Qin Chuan
Key Laboratory of Human Diseases Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Comparative Medicine Centre, Peking Union Medical Collage (PUMC), Pan Jia Yuan Nan Li No. 5, Chao Yang District, Beijing, 100021 China.
Indian J Virol. 2012 Dec;23(3):270-7. doi: 10.1007/s13337-012-0076-1. Epub 2012 Sep 28.
The study was to evaluate the long term immunological efficacy of pandemic 2009 H1N1 influenza live virus infection and split vaccine against the homologous virus challenge in ferrets. Antibodies in ferrets were monitored by haemagglutination inhibition (HI) assay for 200 days, the HI titers of both infected-only and vaccinated plus infected ferrets could maintain a high level for at least 182 days, without significant difference between the two infected groups. While one-dose and two-dose vaccinated ferrets could last a moderate antibody titers for 81 days, with its peak value at day 7 post immunization. After the virus challenge at day 207, the two groups of vaccinated ferrets shed virus for longer time than the two infected groups, while the latter two groups basically did not shed any virus particles. Furthermore, the vaccinated and infected ferrets which were sacrificed at day 211 exerted moderate immune protection against the challenge by alleviating clinical signs and lung lesion without obvious difference between groups. These data supported that both one-dose and two-dose vaccination of 2009 influenza A (H1N1) split vaccine conferred a moderate protection against challenge after 207 days, and there was no significant difference between the two groups. Either the infected only or vaccinated plus infected ones exerted more effective protective immune than one-dose and two-dose vaccination against the challenge, especially in preventing virus shedding, and vaccination primed before infection had no additional efficacy.
该研究旨在评估2009年大流行H1N1流感活病毒感染及裂解疫苗对雪貂同源病毒攻击的长期免疫效果。通过血凝抑制(HI)试验对雪貂体内抗体进行了200天的监测,仅感染组和接种疫苗加感染组的HI效价均可维持高水平至少182天,两组感染组之间无显著差异。单剂量和双剂量接种疫苗的雪貂抗体效价可维持中等水平81天,免疫后第7天达到峰值。在第207天病毒攻击后,两组接种疫苗的雪貂排毒时间比两组感染组更长,而后两组基本未排出任何病毒颗粒。此外,在第211天处死的接种疫苗和感染的雪貂对攻击具有中等程度的免疫保护作用,可减轻临床症状和肺部病变,组间无明显差异。这些数据支持,2009年甲型(H1N1)流感裂解疫苗单剂量和双剂量接种在207天后均对攻击具有中等程度的保护作用,两组之间无显著差异。仅感染组或接种疫苗加感染组对攻击的保护性免疫比单剂量和双剂量接种更有效,尤其是在预防病毒排毒方面,感染前接种疫苗没有额外效果。